Last reviewed · How we verify
NCT04530539
The Effect of Melatonin and Vitamin C on COVID-19
Completed
NA
Last updated 17 August 2022
What this trial tests
NA trial testing Vitamin C in Covid19 in 122 participants. Completed in 11 August 2022.
Timeline
5 October 2020
Primary endpoint
11 August 2022
11 August 2022
11 August 2022
Quick facts
| Lead sponsor | Lancaster General Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 122 |
| Start date | 5 October 2020 |
| Primary completion | 11 August 2022 |
| Estimated completion | 11 August 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
Conditions studied
- Covid19 — all drugs for Covid19 →
- SARS-CoV Infection — all drugs for SARS-CoV Infection →
Sponsor
Lancaster General Hospital
Who can join
50 and older, any sex, with Covid19 or SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a double-blind placebo controlled trial that seeks to evaluate the impact of melatonin and vitamin C on symptoms and outcomes of patients with COVID-19.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression.
Beltrán-García J, Osca-Verdegal R, Pallardó FV, Ferreres J, et al · · 2020 · cited 103× · PMID 33003552 · DOI 10.3390/antiox9100936 -
Role of vitamins and minerals as immunity boosters in COVID-19.
Kumar P, Kumar M, Bedi O, Gupta M, et al · · 2021 · cited 75× · PMID 34110533 · DOI 10.1007/s10787-021-00826-7 -
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895 -
Traditional Herbal Medicines, Bioactive Metabolites, and Plant Products Against COVID-19: Update on Clinical Trials and Mechanism of Actions.
Alam S, Sarker MMR, Afrin S, Richi FT, et al · · 2021 · cited 61× · PMID 34122096 · DOI 10.3389/fphar.2021.671498 -
Micronutrients, Phytochemicals and Mediterranean Diet: A Potential Protective Role against COVID-19 through Modulation of PAF Actions and Metabolism.
Detopoulou P, Demopoulos CA, Antonopoulou S. · · 2021 · cited 52× · PMID 33573169 · DOI 10.3390/nu13020462 -
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.
Jiang Y, Zhao T, Zhou X, Xiang Y, et al · · 2022 · cited 44× · PMID 35923762 · DOI 10.1002/mco2.154 -
Therapeutic potential of melatonin and melatonergic drugs on K18-hACE2 mice infected with SARS-CoV-2.
Cecon E, Izabelle C, Poder SL, Real F, et al · · 2022 · cited 28× · PMID 34586649 · DOI 10.1111/jpi.12772 -
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
Canedo-Marroquín G, Saavedra F, Andrade CA, Berrios RV, et al · · 2020 · cited 27× · PMID 33362758 · DOI 10.3389/fimmu.2020.569760
Verify or expand the search:
- PubMed search for NCT04530539
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vitamin C
Trials testing the same drug.
- NCT07476443 — Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity · Phase 2, PHASE3 · not yet recruiting
- NCT07414693 — Effect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia · Phase 4 · recruiting
- NCT06971315 — Impact of Vitamin C on Pain Detection and Tolerance Threshold · NA · completed
- NCT06794255 — Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults · NA · recruiting
- NCT07341308 — Does Vitamin C Increase the Body Heat Generated By The Nervous System? · NA · recruiting
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Lancaster General Hospital trials
Trials by the same sponsor.
- NCT05223751 — Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure · NA · terminated
- NCT04759066 — The HEALiX™ Intubated Patient (IP) Pilot Study · NA · withdrawn
- NCT04478773 — Adverse Events of MRI With Abandoned Leads · NA · terminated
- NCT04226365 — Pediatric Concussion Outcomes · Phase 4 · terminated
- NCT03923959 — Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04530539 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lancaster General Hospital
- Last refreshed: 17 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04530539.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing